REPLIGEN CORP — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Repligen completed the BioLife Solutions acquisition on October 6, 2026, strengthening its cell therapy consumables platform. Q3 2026 revenue was $209.3M (11% reported, 12.5% organic growth). The company raised full-year 2026 revenue guidance to $844–$852M (14.5–15.5% reported growth), including ~2.5 percentage-point inorganic tailwind from BioLife net of Polymem divestiture, and projects adjusted operating margin of 16.0–16.3% and adjusted EPS of $2.05–$2.09.
Why this rating
Meaningful M&A for ~$6B company adds recurring consumables revenue, but Q3 showed $41.2M intangible impairment, offsetting gains. Moderate near-term execution risk on integration.
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.